Tags : R/R B-cell Acute Lymphoblastic Leukemia(ALL)


Amgen and Astellas’ Blincyto (blinatumomab, BiTE) Receives Japanese Marketing Approval

Shots: Approval is based on P-III TOWER study administering Blincyto vs standard of care (SOC) CT in ratio (2:1) and P-1b/II Horai study administering Blincyto in Japanese adult and pediatric patients with r/r B-cell precursor ALL, assessing its safety and efficacy P-III TOWER(N=405) (Blincyto vs SOC CT) & P-Ib/II Horai study Results: mOS (7.7mos vs […]Read More